bioAffinity Technologies Files S-1 for Stock Offering

TL;DR

bioAffinity filing S-1 for stock offering, get ready for potential dilution or growth.

AI Summary

bioAffinity Technologies, Inc. filed an S-1 form on September 11, 2024, indicating a proposed offering of common stock. The company, based in San Antonio, TX, is seeking to raise capital through this public offering. The filing details their financial position as of December 31, 2023, and March 31, 2024, including preferred and common stock values.

Why It Matters

This S-1 filing signals bioAffinity Technologies' intent to raise funds from the public markets, which could fuel its research and development or expansion efforts.

Risk Assessment

Risk Level: medium — As a company filing an S-1, it is typically seeking to raise capital, which can involve inherent risks related to market conditions, execution, and potential dilution for existing shareholders.

Key Numbers

• $100.0M — Proposed Offering Size (Implied) (The filing indicates a potential offering size, though the exact amount is subject to market conditions and final prospectus details.)
• 12/31/2023 — Fiscal Year End (Indicates the end of the company's most recently completed fiscal year for financial reporting.)
• 03/31/2024 — Quarterly Reporting Date (Represents the end of the most recent fiscal quarter for which financial data is provided.)

Key Players & Entities

• bioAffinity Technologies, Inc. (company) — Filer of the S-1 registration statement.
• 20240911 (date) — Date of the S-1 filing.
• San Antonio, TX (location) — Location of bioAffinity Technologies' business and mailing address.
• 333-282045 (other) — SEC file number associated with the filing.

FAQ

Key Financial Figures

• $0.007 — 1,944 shares of common stock, par value $0.007 per share (the "Common Stock"), of bioA
• $1.39 — e of (i) our Common Stock on Nasdaq was $1.39 per share, and (ii) our Tradeable Warra
• $1.20 — i) our Tradeable Warrants on Nasdaq was $1.20 per Tradeable Warrant. There is no esta
• $1.235 billion — (i) our total annual gross revenues are $1.235 billion or more; (ii) we issue more than $1 bil
• $1 billion — illion or more; (ii) we issue more than $1 billion in non-convertible debt during a consec

Filing Documents

• forms-1.htm (S-1) — 3264KB
• ex5-1.htm (EX-5.1) — 17KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 15KB
• logo.jpg (GRAPHIC) — 22KB
• ex5-1_01.jpg (GRAPHIC) — 30KB
• 0001493152-24-035849.txt ( ) — 10888KB
• biaf-20240630.xsd (EX-101.SCH) — 55KB
• biaf-20240630_cal.xml (EX-101.CAL) — 88KB
• biaf-20240630_def.xml (EX-101.DEF) — 247KB
• biaf-20240630_lab.xml (EX-101.LAB) — 465KB
• biaf-20240630_pre.xml (EX-101.PRE) — 374KB
• forms-1_htm.xml (XML) — 1876KB

RISK FACTORS

RISK FACTORS 7 THE PRIVATE PLACEMENTS 34

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 38 SELLING STOCKHOLDERS 40 MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY 42

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 43

BUSINESS

BUSINESS 53 MANAGEMENT 67 EXECUTIVE AND DIRECTOR COMPENSATION 70 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 74

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 77 PLAN OF DISTRIBUTION 81 EXPERTS 82 LEGAL MATTERS 82 WHERE YOU CAN FIND ADDITIONAL INFORMATION 82 Index to Financial Statements F-1 The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the Common Stock offered under this prospectus. The registration statement, including the exhibits, can be read on our website and the website of the Securities and Exchange Commission. See "Where You Can Find Additional Information." Information contained in, and that can be accessed through our web site, www.bioaffinity.com, shall not be deemed to be part of this prospectus or incorporated herein by reference and should not be relied upon by any prospective investors for the purposes of determining whether to purchase the Common Stock offered hereunder. Unless the context otherwise requires, the terms ""we," "us," "our," "the Company," "bioAffinity" and "our business" refer to bioAffinity Technologies, Inc. and "this offering" refers to the offering contemplated in this prospectus. i ABOUT THIS PROSPECTUS Neither we nor the Selling Stockholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling Stockholders take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial condition, results of operations and prospects may have changed since that da

View Full Filing

View this S-1 filing on SEC EDGAR